Leukotriene receptor antagonist reduces need for inhaled corticosteroids

The leukotriene receptor antagonist montelukast allows asthmatic patients to reduce their use of inhaled corticosteroids, a randomised placebo controlled trial has shown (p 87). Lofdahl et al found that patients given 10 mg daily montelukast could cut their use of inhaled corticosteroids by 47% compared with 30% in the placebo group. However, the study did not examine the effect of montelukast beyond 12 weeks and little is known about the long term effects of the drug.

CiteULike    Complore    Connotea    Del.icio.us    Digg    Reddit    StumbleUpon    Technorati    Twitter    What's this?

Relevant Article

Randomised, placebo controlled trial of effect of a leukotriene receptor antagonist, montelukast, on tapering inhaled corticosteroids in asthmatic patients

Claes-Göran Löfdahl, Theodore F Reiss, Jonathan A Leff, Elliot Israel, Michael J Noonan, Albert F Finn, Beth C Seidenberg, Thomas Capizzi, Sudeep Kundu, and Philippe Godard
BMJ 1999 319: 87-90. [Abstract] [Full Text] [PDF]